Diflunisal
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Diflunisal: From Pain and Arthritis to Acromesomelic Dysplasia (Hunter-Thompson Type)
One-Sentence Summary
Diflunisal is a salicylate-derived NSAID (non-steroidal anti-inflammatory drug) known for its analgesic and anti-inflammatory effects in musculoskeletal conditions such as pain and arthritis. The TxGNN model predicts it may be effective for Acromesomelic Dysplasia, Hunter-Thompson Type — a rare genetic skeletal dysplasia caused by GDF5/CDMP1 mutations — however no clinical trials and no publications currently support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Pain relief and inflammatory musculoskeletal conditions (arthritis, mild-to-moderate pain) |
| Predicted New Indication | Acromesomelic Dysplasia, Hunter-Thompson Type |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the current dataset. Based on established pharmacology, Diflunisal is a difluorophenyl derivative of salicylic acid that acts as a dual COX-1/COX-2 inhibitor, suppressing prostaglandin synthesis to produce analgesic and anti-inflammatory effects. It is structurally related to aspirin but has a longer half-life (~8–12 hours) and improved gastrointestinal tolerability relative to conventional salicylates.
Acromesomelic dysplasia, Hunter-Thompson type, is a rare autosomal recessive skeletal dysplasia caused by loss-of-function mutations in the GDF5/CDMP1 gene. This disrupts BMP (bone morphogenetic protein) signaling during embryonic skeletal development, resulting in characteristic shortening of the forearms and lower legs (acromesomelia). The condition is a structural developmental defect, not an inflammatory disease.
The mechanistic rationale for this TxGNN prediction is weak. COX-1/COX-2 inhibition has no known intersection with GDF5/BMP signaling pathways, and prostaglandin suppression cannot correct or modify the underlying gene-level skeletal defect. Diflunisal could theoretically provide symptomatic pain relief in affected individuals, but this represents a general NSAID property rather than a disease-specific repurposing opportunity. The model’s high prediction score likely reflects structural proximity in the drug-disease knowledge graph rather than genuine therapeutic biology.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Acromesomelic dysplasia, Hunter-Thompson type is a genetic structural bone defect driven by GDF5/CDMP1 mutations; Diflunisal’s COX inhibition mechanism has no pathway-level connection to BMP signaling and cannot modify the underlying disease, making this a non-viable repurposing candidate.
To proceed, the following is needed:
- MOA data from DrugBank to confirm or refute any novel mechanistic link (e.g., off-target BMP pathway interactions)
- TFDA/SmPC documentation for complete safety profile assessment
- Preclinical evidence demonstrating any GDF5/BMP pathway modulation before any clinical hypothesis generation is warranted
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.